Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

70P - Treatment patterns and overall survival (OS) in patients with advanced BRAF mutant (mt) melanoma treated with immunotherapy and targeted therapy (TT) in a real-world setting

Date

09 Dec 2020

Session

e-Poster Display Session

Presenters

Michael Atkins

Citation

Annals of Oncology (2020) 31 (suppl_7): S1441-S1451. 10.1016/annonc/annonc392

Authors

M. Atkins1, C. Julian2, M. Secrest2, J. Lee2, A. Abajo3

Author affiliations

  • 1 Georgetown Lombardi Comprehensive Cancer Center, Washington/US
  • 2 Genentech, Inc, South San Francisco/US
  • 3 F. Hoffmann-La Roche Ltd, Basel/CH
More

Abstract 70P

Background

This retrospective, observational, non-interventional cohort study aimed to assess OS in patients with advanced BRAFmt melanoma who received checkpoint inhibitors (CPI) and/or BRAF-MEK TT as first- (1L) and second-line (2L) treatment and the impact of treatment sequence (TxS).

Methods

Patients diagnosed with advanced BRAFmt melanoma between Jan, 2011 and June, 2020 in the nationwide Flatiron Health electronic health record-derived de-identified database were included if they were ≥18 years, treated after January 2015 with 1L CPI (ipilimumab, nivolumab or pembrolizumab) or 1L TT (dabrafenib/trametinib, binimetinib/encorafenib or cobimetinib/vemurafenib), had 6 months follow-up and had 2 visits before starting 1L therapy. Cox proportional hazard models adjusted for baseline confounders were used to investigate the association of OS with type of treatment.

Results

A total of 853 patients were included in the analysis with 553 (64.8%)/300 (35.2%) and 155 (54%)/132 (46%) patients receiving CPI and TT, respectively in 1L and 2L. Median (CI) time to next treatment was 9.7 (7.5-13.0) and 7.2 (6.0-8.4) months for patients receiving CPI and TT in 1L, respectively. No statistically significant difference in OS was observed between those treated with TT as compared with CPI in 1L (HR: 1.17; CI: 0.90-1.56) and 2L (HR: 1.00; CI: 0.61-1.79) after adjusting for age, region, practice type, year of initial diagnosis, lactate dehydrogenase, albumin, Eastern Cooperative Oncology Group performance status, number of metastases and presence of brain and/or liver metastases. For patients receiving both CPI and TT sequentially, median (CI) OS was 21.5 (16.2-25.8) months for the CPI>TT cohort (n=123) and 18.2 (13.8-25.1) months for the TT>CPI cohort (n=115).

Conclusions

In the absence of standardized treatment for patients with advanced BRAFmt melanoma, CPI and TT are the preferred options with more patients initiating treatment with CPI in the real-world setting. In patients requiring 2L therapy, OS outcomes seem comparable irrespective of TxS. Whether TT or CPI should be administered first to specific populations requires randomized prospective evaluation.

Editorial acknowledgement

Support for third-party writing assistance, furnished by Denise Kenski, PhD, of Health Interactions, Inc, was provided by F. Hoffmann-La Roche Ltd.

Legal entity responsible for the study

Genentech, Inc.

Funding

Genentech, Inc.

Disclosure

M.B. Atkins: Advisory/Consultancy: BMS, Merck, Novartis, Arrowhead, Pfizer, Genentech-Roche, Exelixis, Eisai, Aveo, ImmunoCore, Iovance, Surface, COTA, Idera, Agenus, Apexigen, TRV, Neoleuken, Adagene, Werewolf, Fathom, Pneuma, Leads, Pyxis Oncology, PACT, Elpis, X4Pharma; Research grant/Funding (institution): BMS, Merck, Pfizer; Shareholder/Stockholder/Stock options: Werewolf, Pyxis Oncology, Elpis. C. Julian: Research grant/Funding (institution), Shareholder/Stockholder/Stock options, Full/Part-time employment: Genentech, Inc. M.H. Secrest: Shareholder/Stockholder/Stock options, Full/Part-time employment: Roche. J. Lee: Shareholder/Stockholder/Stock options, Full/Part-time employment: Genentech, Inc. A.M. Abajo: Full/Part-time employment: F. Hoffmann-La Roche Ltd. E. McKenna: Full/Part-time employment: Genentech, Inc; Shareholder/Stockholder/Stock options: F. Hoffmann-La Roche Ltd.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings